Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global nanotechnology-based drug delivery market 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Technology trends
2.1.4 Application trends
Chapter 3 Nanotechnology-based Drug Delivery Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic conditions
3.2.1.2 Increasing preference for personalized medicines
3.2.1.3 Increasing advancements in nanomaterials
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory policies
3.2.2.2 High cost of nanotechnology drug delivery technique
3.3 Growth potential analysis
3.3.1 By technology
3.3.2 By application
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Recent advancement and future prospects
3.7 FDA-approved nanotechnology-based products and clinical trials
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Competitive analysis of major market players
4.5 Strategy dashboard, 2022
Chapter 5 Nanotechnology-based Drug Delivery Market Size and Forecast, By Technology (USD Million)
5.1 Key trends, by technology
5.2 Nanocrystals
5.3 Nanoparticles
5.4 Liposomes
5.5 Micelles
5.6 Other technologies
Chapter 6 Nanotechnology-based Drug Delivery Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Neurology
6.3 Oncology
6.4 Cardiovascular/Physiology
6.5 Anti-inflammatory/Immunology
6.6 Anti-infective
6.7 Other applications
Chapter 7 Nanotechnology-based Drug Delivery Market Size and Forecast, By Region (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East & Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 Rest of Middle East & Africa
Chapter 8 Company Profiles
8.1 AbbVie Inc.
8.2 BlueWillow Biologics
8.3 Camurus AB
8.4 Celgene, Inc.
8.5 Cristal Therapeutics
8.6 Johnson and Johnson
8.7 Merck and Co., Inc
8.8 Nanobiotix
8.9 NanoCarrier Co. Ltd.
8.10 NanOlogy LLC
8.11 Novartis International AG
8.12 Starpharma Holdings Limited
